Log in to save to my catalogue

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients ol...

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients ol...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_59674

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

About this item

Full title

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2012-09, Vol.13 (9), p.916-926

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years. We did a randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma. Methods Patients with newly diagnosed glioblastoma were recruited f...

Alternative Titles

Full title

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_umu_59674

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_59674

Other Identifiers

ISSN

1470-2045,1474-5488

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(12)70265-6